Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125095282 | 12509528 | 2 | F | 201603 | 20160708 | 20160629 | 20160715 | EXP | BR-JNJFOC-20160613443 | JANSSEN | 50.12 | YR | A | F | Y | 0.00000 | 20160715 | CN | BR | BR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125095282 | 12509528 | 1 | SS | REMICADE | INFLIXIMAB | 1 | Intravenous (not otherwise specified) | U | U | 0 | 5 | DF | LYOPHILIZED POWDER | ||||||
| 125095282 | 12509528 | 2 | SS | REMICADE | INFLIXIMAB | 1 | Intravenous (not otherwise specified) | U | U | 0 | 5 | DF | LYOPHILIZED POWDER | ||||||
| 125095282 | 12509528 | 3 | SS | REMICADE | INFLIXIMAB | 1 | Intravenous (not otherwise specified) | U | U | 0 | LYOPHILIZED POWDER | ||||||||
| 125095282 | 12509528 | 4 | SS | REMICADE | INFLIXIMAB | 1 | Intravenous (not otherwise specified) | U | U | 0 | 5 | DF | LYOPHILIZED POWDER | ||||||
| 125095282 | 12509528 | 5 | PS | REMICADE | INFLIXIMAB | 1 | Intravenous (not otherwise specified) | U | U | 103772 | 500 | MG | LYOPHILIZED POWDER |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125095282 | 12509528 | 1 | Psoriatic arthropathy |
| 125095282 | 12509528 | 2 | Psoriatic arthropathy |
| 125095282 | 12509528 | 3 | Psoriatic arthropathy |
| 125095282 | 12509528 | 4 | Psoriatic arthropathy |
| 125095282 | 12509528 | 5 | Psoriatic arthropathy |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125095282 | 12509528 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125095282 | 12509528 | Arthritis infective | |
| 125095282 | 12509528 | Infection | |
| 125095282 | 12509528 | Injury | |
| 125095282 | 12509528 | Localised infection | |
| 125095282 | 12509528 | Peripheral swelling | |
| 125095282 | 12509528 | Psoriasis | |
| 125095282 | 12509528 | Psoriatic arthropathy | |
| 125095282 | 12509528 | Pyrexia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125095282 | 12509528 | 1 | 20150701 | 0 | ||
| 125095282 | 12509528 | 2 | 20150618 | 0 | ||
| 125095282 | 12509528 | 3 | 20160309 | 0 | ||
| 125095282 | 12509528 | 4 | 20160113 | 0 | ||
| 125095282 | 12509528 | 5 | 20150618 | 0 |